TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) just unveiled an update.
Lumos Diagnostics has issued an addendum to its Notice of Annual General Meeting, addressing shareholder queries regarding the timing and vesting conditions of performance rights for its CEO, Douglas Ward. The addendum does not alter the validity of previously submitted proxy votes and provides shareholders with additional details to consider before the meeting on October 24, 2025.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.
Average Trading Volume: 8,250,051
Technical Sentiment Signal: Buy
Current Market Cap: A$141.5M
Learn more about LDX stock on TipRanks’ Stock Analysis page.